BidaskClub upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a hold rating to a buy rating in a report released on Friday, BidAskClub reports.

ALNY has been the subject of a number of other research reports. Morgan Stanley lowered their price objective on Alnylam Pharmaceuticals from $126.00 to $124.00 and set an overweight rating for the company in a research note on Wednesday, August 7th. Cowen lowered their price objective on Alnylam Pharmaceuticals from $147.00 to $120.00 and set an outperform rating for the company in a research note on Wednesday, August 7th. Piper Jaffray Companies set a $145.00 price objective on Alnylam Pharmaceuticals and gave the company a buy rating in a research note on Tuesday, September 10th. Goldman Sachs Group reiterated a neutral rating and set a $80.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Thursday, May 23rd. Finally, Stifel Nicolaus set a $116.00 price objective on Alnylam Pharmaceuticals and gave the company a buy rating in a research note on Tuesday, September 3rd. Five analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of Buy and an average target price of $116.13.

Shares of NASDAQ:ALNY opened at $84.77 on Friday. The stock has a fifty day simple moving average of $80.42 and a two-hundred day simple moving average of $78.97. The stock has a market capitalization of $9.47 billion, a price-to-earnings ratio of -11.20 and a beta of 2.35. Alnylam Pharmaceuticals has a 12-month low of $60.27 and a 12-month high of $97.84. The company has a current ratio of 6.28, a quick ratio of 6.16 and a debt-to-equity ratio of 0.17.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($2.02) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($2.06) by $0.04. The business had revenue of $38.20 million during the quarter, compared to analysts’ expectations of $42.24 million. Alnylam Pharmaceuticals had a negative return on equity of 56.42% and a negative net margin of 848.70%. The firm’s quarterly revenue was up 27.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.61) earnings per share. As a group, equities research analysts predict that Alnylam Pharmaceuticals will post -8.21 EPS for the current year.

Several institutional investors have recently bought and sold shares of ALNY. Maverick Capital Ltd. increased its holdings in shares of Alnylam Pharmaceuticals by 31.9% in the 2nd quarter. Maverick Capital Ltd. now owns 4,236,016 shares of the biopharmaceutical company’s stock worth $307,365,000 after purchasing an additional 1,025,629 shares in the last quarter. FMR LLC increased its holdings in shares of Alnylam Pharmaceuticals by 5.2% in the 1st quarter. FMR LLC now owns 15,945,666 shares of the biopharmaceutical company’s stock worth $1,490,122,000 after purchasing an additional 791,113 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 7.6% in the 2nd quarter. Vanguard Group Inc. now owns 9,316,686 shares of the biopharmaceutical company’s stock worth $676,018,000 after purchasing an additional 657,595 shares in the last quarter. Farallon Capital Management LLC increased its holdings in shares of Alnylam Pharmaceuticals by 120.0% in the 2nd quarter. Farallon Capital Management LLC now owns 1,100,000 shares of the biopharmaceutical company’s stock worth $79,816,000 after purchasing an additional 600,000 shares in the last quarter. Finally, Baillie Gifford & Co. increased its holdings in shares of Alnylam Pharmaceuticals by 9.3% in the 2nd quarter. Baillie Gifford & Co. now owns 6,213,470 shares of the biopharmaceutical company’s stock worth $450,850,000 after purchasing an additional 528,966 shares in the last quarter. 94.20% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.

Featured Article: How are dividend achievers different from dividend aristocrats?

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.